Travere Therapeutics (TVTX) Stock Overview
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TVTX Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Travere Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.29 |
| 52 Week High | US$60.10 |
| 52 Week Low | US$15.03 |
| Beta | 1.11 |
| 1 Month Change | 8.17% |
| 3 Month Change | 33.61% |
| 1 Year Change | 232.88% |
| 3 Year Change | 254.69% |
| 5 Year Change | 312.08% |
| Change since IPO | 993.01% |
Recent News & Updates
Narrative Update • Jul 02
TVTX: Expanded Kidney Franchise And IP Runway Will Shape Risk Reward Balance
Travere Therapeutics sees its analyst price target framework move higher to a fair value estimate of about $58.36 from roughly $53.57, as analysts factor in stronger expectations around the Filspari launch in focal segmental glomerulosclerosis, extended Filspari IP protection and the addition of civorebrutinib to the rare kidney disease pipeline, while also applying a slightly higher discount rate and a more conservative profit margin and P/E profile. Analyst Commentary Recent research on Travere Therapeutics points to a generally constructive view on the stock, with multiple firms revisiting their models around Filspari and the broader rare kidney disease pipeline.
Narrative Update • Jun 18
TVTX: Extended Kidney Franchise Exclusivity Will Drive Bullish Stock Repricing
Analysts have lifted the implied fair value estimate for Travere Therapeutics to $70 from about $65.83, citing higher price targets tied to the civorebrutinib licensing deal in rare kidney disease and extended Filspari patent protection in IgAN, which feeds into updated revenue and profitability assumptions. Analyst Commentary Recent Street research around Travere Therapeutics centers on two key themes that matter for investors following the stock: the civorebrutinib licensing deal in rare kidney disease and the extended Filspari patent protection in IgAN.Recent updates
Narrative Update • Jul 02
TVTX: Expanded Kidney Franchise And IP Runway Will Shape Risk Reward Balance
Travere Therapeutics sees its analyst price target framework move higher to a fair value estimate of about $58.36 from roughly $53.57, as analysts factor in stronger expectations around the Filspari launch in focal segmental glomerulosclerosis, extended Filspari IP protection and the addition of civorebrutinib to the rare kidney disease pipeline, while also applying a slightly higher discount rate and a more conservative profit margin and P/E profile. Analyst Commentary Recent research on Travere Therapeutics points to a generally constructive view on the stock, with multiple firms revisiting their models around Filspari and the broader rare kidney disease pipeline.Narrative Update • Jun 18
TVTX: Extended Kidney Franchise Exclusivity Will Drive Bullish Stock Repricing
Analysts have lifted the implied fair value estimate for Travere Therapeutics to $70 from about $65.83, citing higher price targets tied to the civorebrutinib licensing deal in rare kidney disease and extended Filspari patent protection in IgAN, which feeds into updated revenue and profitability assumptions. Analyst Commentary Recent Street research around Travere Therapeutics centers on two key themes that matter for investors following the stock: the civorebrutinib licensing deal in rare kidney disease and the extended Filspari patent protection in IgAN.Narrative Update • Jun 03
TVTX: Extended Kidney Franchise Exclusivity Will Support Bullish Repricing
Analysts have lifted the implied fair value for Travere Therapeutics stock from $49.00 to about $65.83, citing higher price targets linked to expanded pipeline potential around civorebrutinib and extended Filspari patent protection, which is incorporated into updated revenue, profit margin, and future P/E assumptions. Analyst Commentary Bullish analysts have been highlighting two main pillars for Travere Therapeutics: the expanding pipeline with civorebrutinib and the potential for longer Filspari exclusivity.Narrative Update • May 15
TVTX: FSGS Approval And 90 Day Catalyst Window Will Reshape Expectations
The analyst price target for Travere Therapeutics has shifted from $49.57 to $53.57, with analysts citing recent target increases across several firms and updated assumptions around profitability and P/E expectations as key drivers of the revision. Analyst Commentary Bullish and bearish analysts are looking at the same data for Travere Therapeutics and reaching different conclusions on how much value is already reflected in the stock and how much execution risk still sits ahead.Narrative Update • Apr 28
TVTX: FSGS Approval And 90 Day Catalyst Window Will Drive Repricing
Analysts raised the Travere Therapeutics fair value estimate from $42.50 to about $49.57, reflecting updated assumptions around higher revenue growth, a slightly different discount rate, a modestly adjusted profit margin, and a higher future P/E that align with the recent wave of increased Street price targets following the FSGS approval and related research updates. Analyst Commentary Bullish and cautious views on Travere Therapeutics have both surfaced in recent Street research, with several firms adjusting price targets and ratings following the FSGS approval and related updates.Seeking Alpha • Apr 21
Travere Therapeutics: Still Undervalued Post FSGS Approval
Summary Travere Therapeutics is rated a BUY following Filspari's landmark FDA approval for FSGS, making it the only approved therapy for this indication. TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari’s commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs. Key risks include commercial execution, rising IgAN competition, and patent expiration, but FSGS exclusivity and orphan drug protections extend into 2030–2033. Read the full article on Seeking AlphaNarrative Update • Apr 14
TVTX: FSGS Approval And 90 Day Catalyst Window Will Support Upside
Travere Therapeutics has had its analyst price target raised slightly to $42.50, as analysts incorporate updated assumptions on growth, margins and future P/E in light of recent upgrades, higher targets and an FSGS approval. Analyst Commentary Street research on Travere Therapeutics has been active around the recent FSGS approval, with several firms revising rating stances and price targets.Narrative Update • Mar 31
TVTX: Extended Review And 90 Day Catalyst Watch Will Support Bullish Repricing
Analysts have made a modest trim to their Travere Therapeutics price targets, with a net change of $3. This reflects mixed revisions around the Filspari sNDA review and a new 90 day catalyst watch that keeps regulatory outcomes and near term catalysts in focus.Narrative Update • Mar 17
TVTX: PDUFA Extension And Refined Assumptions Will Support Bullish Repricing
Analysts have lifted their average price target on Travere Therapeutics by a few dollars to reflect updated views on Filspari’s regulatory path, as well as refined expectations for revenue growth, profitability, and future P/E multiples. Analyst Commentary Bullish analysts are framing the latest developments around Filspari as a clear support for their refreshed valuation work, especially as the regulatory review process becomes more defined.Narrative Update • Mar 03
TVTX: PDUFA Extension Will Reduce Regulatory Tail Risk And Support Repricing
Analysts have nudged their blended price target on Travere Therapeutics up by a few dollars, reflecting slightly improved profit margin assumptions and comfort around the recent Filspari PDUFA extension, which they say removes a potential worst case regulatory outcome. Analyst Commentary Recent Street research on Travere Therapeutics has centered on the Filspari PDUFA extension and its implications for regulatory risk, valuation, and execution.Narrative Update • Feb 17
TVTX: FSGS Regulatory Extension And Kidney Data Will Drive A Constructive Outlook
The updated analyst price target for Travere Therapeutics moves to $42.36 from $41.64. Analysts point to incremental adjustments in revenue growth, profit margin expectations and the lower future P/E assumption.
Narrative Update • Feb 02
TVTX: PDUFA Extension And Regulatory Clarity Will Shape Balanced Risk Profile
Analysts now place fair value for Travere Therapeutics at about US$32.41 per share, up from US$20.00, citing updated assumptions around profitability, a lower future P/E multiple, and recent research that frames the Filspari PDUFA extension as removing a worst case regulatory outcome, despite one firm trimming its price target. Analyst Commentary Street research around Travere Therapeutics has been mixed, with some firms highlighting regulatory progress on Filspari while others make more cautious adjustments to their models and price targets.Analysis Article • Jan 24
Benign Growth For Travere Therapeutics, Inc. (NASDAQ:TVTX) Underpins Stock's 27% Plummet
Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shares have retraced a considerable 27% in the last month, reversing a fair...Narrative Update • Jan 19
TVTX: PDUFA Extension And Kidney Data Will Support Future Bullish Repricing
Narrative Update on Travere Therapeutics Analysts have trimmed their price target on Travere Therapeutics by $4 while keeping fair value broadly unchanged. This reflects slightly higher discount rate assumptions and updated expectations around Filspari's regulatory timing after the FDA's PDUFA extension, which some view as removing the risk of an immediate Complete Response Letter.Narrative Update • Jan 05
TVTX: Kidney Trial Data And Regulatory Risks Will Shape A Measured Outlook
Analysts have slightly lifted their fair value estimate for Travere Therapeutics to about US$41.64 per share from roughly US$41.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. What's in the News New Phase 3 DUPLEX Study data for FILSPARI in focal segmental glomerulosclerosis, with patients more likely to reach proteinuria levels below 0.7 g/g compared with maximum dose irbesartan.Narrative Update • Dec 15
TVTX: Phase 3 Kidney Data Will Support A Bullish Repricing
Analysts have modestly raised their price target on Travere Therapeutics from 47 dollars to 49 dollars. This reflects expectations for slightly stronger revenue growth and profit margins that more than offset a higher assumed discount rate and a lower future earnings multiple.Narrative Update • Dec 01
TVTX: Regulatory Outlook Will Likely Improve Following FDA Advisory Committee Meeting Cancellation
Analysts have increased their price targets for Travere Therapeutics. One firm raised its projection by $5 to $25, citing growing confidence in regulatory approval following the FDA's decision to cancel the advisory committee meeting for Filspari.Narrative Update • Nov 17
TVTX: FDA Advisory Committee Meeting Cancellation Will Signal Major Regulatory Progress
The analyst price target for Travere Therapeutics has increased by $3.00 to $41.50. Analysts cite improved approval odds for Filspari following the FDA's cancellation of a planned advisory committee meeting and a strengthened earnings outlook.Analysis Article • Nov 06
Travere Therapeutics, Inc. (NASDAQ:TVTX) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shares have continued their recent momentum with a 29% gain in the last...Narrative Update • Nov 02
TVTX: Recent Regulatory Momentum Will Drive FSGS And IgAN Market Leadership
Travere Therapeutics' analyst price target increased from $35.71 to $38.50 per share, as analysts point to positive regulatory developments and continued strong prospects for Filspari, driving their upward revisions. Analyst Commentary Bullish Takeaways Bullish analysts highlight the cancellation of the FDA advisory committee meeting as a significant positive.Analysis Article • Sep 06
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified
Despite an already strong run, Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shares have been powering on, with a gain of...Narrative Update • Sep 04
FSGS And IgA Nephropathy Expansion Will Transform Market Reach
The consensus analyst price target for Travere Therapeutics has been raised to $35.71, reflecting strong Q2 results and robust demand growth for Filspari in IgAN, as well as optimism around upcoming FDA action dates and continued commercial execution. Analyst Commentary Expectations for meaningful upside driven by two near-term FDA action dates.
New Narrative • Apr 25
Expanded Approvals Will Broaden IgAN And FSGS Treatment Options
FILSPARI's expanded approval and ongoing studies position it for increased revenue from treating renal diseases, with potential market expansion from the new sNDA submission for FSGS.Seeking Alpha • Mar 07
Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Summary Travere Therapeutics, Inc.'s Filspari received full FDA approval last September, due to its significantly reducing kidney function decline in IgA nephropathy, which boosted the company's share price by ~100%. Despite $132m revenue from Filspari in 2024, Travere made a heavy loss of >$(300m) and has not provided detailed 2025 guidance, causing market jitters. Competitive threats from Novartis and others loom, but Filspari's full approval and potential FSGS label expansion offer growth opportunities. I'm downgrading TVTX stock to “Hold” due to its relatively high valuation, heavy losses, and competitive threats; I'm a little cautious about 2025 performance without clear guidance. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Summary Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setbacks in FSGS trials, ongoing studies and FDA involvement suggest potential future approval, bolstered by proteinuria reduction as a validated surrogate endpoint. Financially, TVTX faces high operating expenses and cash runway concerns but aims to extend runway to 2028 through restructuring and secondary offerings. The HCU program faces delays due to supply chain issues, impacting company valuation; cautious optimism remains for revenue growth and potential FSGS approval. Read the full article on Seeking AlphaSeeking Alpha • Sep 30
Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Summary Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval, and its market potential is significant if indications expand. Travere faces risks from supply constraints and paused Pegtibatinase trial, but these are seen as temporary headwinds rather than long-term issues. TVTX's valuation appears reasonable, with a forward P/S of 3.2. Still, I believe some dilution is likely in the near term. I deem TVTX stock a "Buy" due to promising Filspari approval, manageable cash runway, and potential market expansion despite recent setbacks. Read the full article on Seeking AlphaSeeking Alpha • Aug 30
Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Summary Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's unique dual-pathway mechanism and promising clinical data make FDA denial unlikely, supporting a bullish outlook. Travere's financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome. With a positive PDUFA outcome, Travere's market cap could exceed $1 billion in 2024, I believe offering up to 40% upside from current levels. The longer-term picture is cloudier. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Travere Therapeutics: Restructuring Away From Disaster
Summary Travere Therapeutics faces challenges following disappointing data from its PROTECT trial in September 2023. The FDA granted accelerated approval for Travere's FILSPARI, but its continued approval is contingent upon confirmation of clinical benefit in the ongoing PROTECT Study. Accelerated approval allows the FDA to approve a drug based on surrogate endpoints, but it requires subsequent validation in a confirmatory study. Read the full article on Seeking AlphaShareholder Returns
| TVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | -3.1% | -0.9% |
| 1Y | 232.9% | 32.8% | 19.4% |
Return vs Industry: TVTX exceeded the US Biotechs industry which returned 34.9% over the past year.
Return vs Market: TVTX exceeded the US Market which returned 20.3% over the past year.
Price Volatility
| TVTX volatility | |
|---|---|
| TVTX Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TVTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TVTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 497 | Eric Dube | travere.com |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
Travere Therapeutics, Inc. Fundamentals Summary
| TVTX fundamental statistics | |
|---|---|
| Market cap | US$5.26b |
| Earnings (TTM) | -US$45.64m |
| Revenue (TTM) | US$536.20m |
9.8x
P/S Ratio-114.7x
P/E RatioIs TVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TVTX income statement (TTM) | |
|---|---|
| Revenue | US$536.20m |
| Cost of Revenue | US$236.22m |
| Gross Profit | US$299.98m |
| Other Expenses | US$345.62m |
| Earnings | -US$45.64m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 55.95% |
| Net Profit Margin | -8.51% |
| Debt/Equity Ratio | 316.1% |
How did TVTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 07:37 |
| End of Day Share Price | 2026/07/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Travere Therapeutics, Inc. is covered by 30 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guyn Kim | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |
| Dae Gon Ha | BTIG |